

WuXi Biologics Wuhan Site Resumes Operations

14 February 2020 | News

It's back to work for Wuxi's Employees



WuXi Biologics is closely monitoring the coronavirus outbreak. The firm said its management team is working vigilantly to execute Business Continuity Plan to mitigate any potential risk. All three operating sites in China, namely Wuxi, Shanghai and Suzhou, has resumed operations after the Chinese New Year break.

"Overall, approximately 6% of our staff have traveled to Wuhan, transited through Wuhan or had contact with people coming from Wuhan. No employee has been diagnosed with the infection. We are closely monitoring the health of every employee and have implemented strict back-to-work procedures to protect our employees. Approximately 85% of staff are already back to the cities in which they work. We have sufficient number of staff to resume operations," the firm said.

"We do not operate in Wuhan and do not have major suppliers from Wuhan. Supplies for labs and manufacturing are not likely affected. In addition, shipment of samples and materials, import and export, and custom clearance are business as usual," the firm further added.

In addition, WuXi Biologics is also working vigilantly to ensure the quality of the products they are manufacturing is not affected by this outbreak. The firm said it has a strong GMP quality system and a robust global supply chain and does not expect to see any negative impact of this outbreak on our GMP operations.

Overseas clients who plan to travel to China are recommended to conduct meetings via videoconferences or teleconferences.

WuXi Biologics has already mobilized a large team of more than 240 scientists and is working closely with global organizations to develop and manufacture multiple neutralizing antibodies to potentially treat the virus infection. In-vitro efficacy of these antibodies will be available next month.

"This situation, which continues to evolve daily, reminds us that we must continue to do the right things for patients. We do not expect to see meaningful negative impact on our business operations in China," the firm said.